RÉSUMÉ
Interleukin-12 (IL-12) is a potent inducer of interferon-gamma production by T cells and is a major factor for the development of T-helper 1 (Th1) cells. It exerts its biological effects through binding to the IL-12 receptor (IL-12R), a heterodimer composed of a 1 and a beta2 subunits. The signaling beta2 chain is expressed on Th1 cells and to a lesser extent on Th0 cells, but not on Th2 cells, rendering these latter cells unresponsive to IL-12. Polymorphisms in the coding region of the IL-12Rbeta2 gene were shown to be associated with atopic disease. Here, we analyzed the 5'-regulatory region of the human IL-12Rbeta2 gene by denaturing high-performance liquid chromatography (Transgenomic WAVE system, San Jose, CA). We found five novel single-nucleotide polymorphisms (SNPs) in the proximal 1.2 kb IL-12Rbeta2 promoter region, i.e. -237C/T, -465A/G, -1023A/G, -1033T/C, and -1035A/G. SNP -465A/G is of particular interest as it determines the integrity of a GATA consensus site. By functional comparison of both -465 alleles in transient transfection assays, we show that promoter activity is increased in case of the -465G allele, disrupting the intact GATA site. Comparison of the prevalence of -465A/G SNP alleles in small cohorts of allergic asthmatic and healthy control individuals provided no evidence for an altered distribution in the asthmatic population. In conclusion, we have identified a novel polymorphic GATA site that may affect transciptional activity of the human IL-12Rbeta2 gene under GATA3-mediated, Th2-polarizing conditions.
Sujet(s)
Régions promotrices (génétique) , Récepteurs aux interleukines/génétique , Région 5' flanquante , Asthme/génétique , Séquence nucléotidique , Séquence consensus , Humains , Données de séquences moléculaires , Polymorphisme de nucléotide simple , Récepteurs à l'interleukine-12RÉSUMÉ
Interleukin 12 (IL-12) is a potent enhancer of interferon gamma production by activated T cells. The high-affinity IL-12 receptor (IL-12R) is a heterodimer of a beta1 and a beta2 subunit. Expression of the signaling IL-12Rbeta2 chain is usually low, as compared with the more abundant beta1 chain, and may be rate-limiting for IL-12 sensitivity. Little is known about the mechanisms controlling IL-12Rbeta2 gene expression. Reporter gene assays in IL-12Rbeta2-expressing Jurkat cells showed that truncation of the region from -151 to -61 abrogated promoter activity. The proximal promoter region does not contain a typical TATA box, suggesting a role for SP-1. Indeed, mutagenesis of the -63 SP-1 consensus site decreased transcription by 50%. Electrophoretic mobility shift experiments confirmed the binding of SP-1 and SP-3 at this site. In contrast, truncation of -252 to -192 increased promoter activity. Likewise, mutagenesis of the consensus nuclear factor of activated T cells site at -206 increased promoter activity by 70%, suggesting silencer activity of this element. Electrophoretic mobility shift experiments with primary Th (T helper) cells showed the formation of a specific, T-cell receptor-inducible complex at this site that is sensitive to cyclosporin A and supershifted with anti-NFATc2 in both Th1 and Th2 cells. Accordingly, cyclosporin A dose-dependently increased IL-12Rbeta2 mRNA expression. These first data on IL-12Rbeta2 gene regulation indicate a TATA-less promoter, depending on SP-1/SP-3 transcription factors, and a negative regulatory NFAT element at -206. This element may contribute to the overall low level of IL-12Rbeta2 expression on Th cells.
Sujet(s)
Protéines de liaison à l'ADN/physiologie , Extinction de l'expression des gènes , Protéines nucléaires , Podophylline/analogues et dérivés , Régions promotrices (génétique) , Récepteurs aux interleukines/génétique , Lymphocytes T auxiliaires/métabolisme , Facteurs de transcription/physiologie , Séquence nucléotidique , Sites de fixation , Régulation de l'expression des gènes , Gènes régulateurs , Humains , Cellules Jurkat , Données de séquences moléculaires , Facteurs de transcription NFATC , Podophylline/métabolisme , Podophyllotoxine/analogues et dérivés , Sous-unités de protéines , ARN messager/analyse , Récepteurs à l'interleukine-12RÉSUMÉ
The interleukin-12 receptor (IL-12R) is composed of two subunits, referred to as beta1 and beta2. Both chains are necessary for high-affinity IL-12 binding and signalling, although only the IL-12Rbeta2 chain contains the intracellular tyrosine residues responsible for STAT4 activation. This study presents the intron-exon organization of the human IL-12Rbeta2-chain gene. Polymerase chain reaction (PCR) primers designed across the cDNA (U46198) were used to trace introns, by comparing PCR product sizes obtained using cDNA and genomic DNA as templates. PCR products spanning introns were sequenced to determine the exact splice sites and flanking regions. The coding region of the gene was found to consist of 15 exons and 14 introns. All intron-exon boundaries are consistent with the consensus sequence for splice junctions (5' GT/AG 3'). Comparison of the intron-exon organization with the human GCSFR gene indicated a remarkably well conserved genomic organization between these two class I cytokine receptors. Interestingly, we identified an alternatively spliced mRNA, encoding a putative, truncated protein, lacking all signalling potential.
Sujet(s)
Exons/génétique , Introns/génétique , Récepteurs aux interleukines/génétique , Épissage alternatif/génétique , Motifs d'acides aminés/génétique , Séquence d'acides aminés , Séquence nucléotidique , Cellules cultivées , Codon stop/génétique , Séquence conservée/génétique , Amorces ADN/génétique , ADN complémentaire/génétique , Humains , Réaction de polymérisation en chaîne , ARN messager/analyse , ARN messager/génétique , Récepteurs aux interleukines/composition chimique , Récepteurs aux interleukines/physiologie , Récepteurs à l'interleukine-12 , Délétion de séquence/génétique , Lymphocytes T/métabolisme , Tyrosine/génétiqueRÉSUMÉ
Gastric inhibitory polypeptide (GIP) concentrations may be influenced by obesity, diabetes, and glucagon deficiency and be under feedback inhibition by insulin. To assess these factors, insulin-dependent diabetic, totally pancreatectomized diabetic, and lean and obese noninsulin-dependent diabetic patients were studied twice, once during partial insulin withdrawal and again when euglycemia was achieved before and after mixed meal ingestion, using an artificial endocrine pancreas. The results were compared to those from weight-matched lean and obese nondiabetic subjects. No significant differences in postprandial GIP responses were found between lean and obese nondiabetic subjects. Despite basal and postprandial hyperglycemia, the GIP responses to the mixed meal were not significantly different between insulin-deficient (insulin-dependent and totally pancreatectomized) patients and lean nondiabetic subjects. In addition, there were no significant differences in postprandial GIP responses between insulin-dependent and totally pancreatectomized patients. In contrast, lean and obese noninsulin-dependent diabetic patients had reduced GIP responses compared to weight-matched nondiabetic subjects (mean +/- SE, 37.9 +/- 5.4 vs. 67.1 +/- 10.8 ng ml-1 240 min-1, respectively; P less than 0.05). This difference was entirely due to the reduced GIP responses in obese noninsulin-dependent diabetic patients compared to those in obese nondiabetic subjects (32.1 +/- 7.9 vs. 76.9 +/- 18.2 ng ml-1 240 min-1, respectively; P less than 0.05); the postprandial GIP responses were not significantly different between lean noninsulin-dependent diabetic patients and lean nondiabetic subjects. Insulin infusion by an artificial endocrine pancreas resulted in postprandial insulin and glucose profiles that approximated those of nondiabetics, but did not significantly alter GIP responses to the mixed meal (48.2 +/- 5.5 ng ml-1 240 min-1) in the 18 diabetic patients compared to results obtained with sc insulin treatment (42.2 +/- 5.2 ng ml-1 240 min-1). In conclusion, postprandial GIP responses are normal in obese nondiabetic subjects and insulin-deficient diabetic patients and are blunted in obese, but not in lean, noninsulin-dependent diabetic patients. In addition, GIP does not appear to be under feedback inhibition by insulin or influenced by glucagon deficiency in diabetes.
Sujet(s)
Diabète de type 1/métabolisme , Diabète de type 2/métabolisme , Diabète/métabolisme , Peptide gastrointestinal/sang , Hormones gastrointestinales/sang , Obésité/métabolisme , Adulte , Sujet âgé , Glycémie/analyse , Duodénum/chirurgie , Humains , Insuline/sang , Insuline/pharmacologie , Adulte d'âge moyen , PancréatectomieRÉSUMÉ
To assess the effects of size, time of day, and sequence of meals on insulin requirements determined by an artificial endocrine pancreas, eight insulin-dependent diabetics ate meals of 12.5%, 25%, and 50% of total calories (30 Kcal/kg) at 0800, 1300, and 1800 on each of 3 separate days in a randomized order in one of two sequences in a three by three Latin square design. Plasma glucose and free insulin concentrations and amounts of insulin infused by the artificial endocrine pancreas were associated with meal size (P less than 0.001) but not with time of day of meal ingestion (analysis of variance). The sequence of meal ingestion did not alter integrated plasma glucose responses, but did influence the meal-related amounts of insulin infused. Thus, consideration should be given to meal size and sequence of meal ingestion but not time of day of meal ingestion when determining prandial iv insulin requirements.
Sujet(s)
Diabète de type 1/traitement médicamenteux , Régime alimentaire , Insuline/administration et posologie , Adulte , Glycémie/métabolisme , Diabète de type 1/sang , Relation dose-effet des médicaments , Ration calorique , Femelle , Glucagon/sang , Humains , Insuline/sang , Insuline/usage thérapeutique , Mâle , Facteurs tempsRÉSUMÉ
The effects of size, time of day and sequence of meal ingestion were determined in healthy subjects using a Latin square design. Plasma glucose, insulin and gastric inhibitory polypeptide, but not glucagon, were correlated with meal size. Plasma glucose, but not insulin, gastric inhibitory polypeptide or glucagon, were greater later in the day. The progressive decline in carbohydrate tolerance from 08.00 to 18.00 h was associated with impaired insulin secretion estimated by C-peptide, and with impaired insulin action.
Sujet(s)
Glycémie/métabolisme , Régime alimentaire , Hydrates de carbone alimentaires/pharmacologie , Adulte , Rythme circadien , Ration calorique , Femelle , Peptide gastrointestinal/sang , Glucagon/sang , Humains , Insuline/sang , MâleRÉSUMÉ
The optimal route for insulin administration by insulin infusion devices has not been established. To assess the differences between the peripheral venous and portal venous routes of insulin administration on postprandial metabolic responses, six alloxan-diabetic dogs were studied on four occasions. On the first, the insulin infusion rates given by the Biostator for disposal of a mixed meal were recorded electronically. On two subsequent occasions, these insulin infusion profiles were administered by a peripheral vein. On an additional occasion, the identical insulin infusion profile was given via the portal vein. No differences were observed in basal or peak plasma glucose, insulin, glucagon, branched chain amino acids, and lactate concentrations between portal and peripheral venous insulin administration. Furthermore, no differences in isotopically ( [2-3H]glucose) determined rates of systemic glucose appearance and disappearance were observed between the two routes. Although preprandial plasma alanine concentrations were greater when insulin was infused via the portal vein, the postprandial increments did not differ from those observed during infusion of insulin by a peripheral vein. These studies suggest that under the current experimental conditions, there appears to be no difference in the disposition of a mixed meal, measured as net whole body glucose appearance and disappearance rates, when insulin is administered in an open-loop fashion via either a peripheral or the portal vein.
Sujet(s)
Diabète expérimental/sang , Pompes à insuline , Alanine/sang , Acides aminés à chaine ramifiée/sang , Animaux , Chiens , Glucagon/sang , Perfusions parentérales , Lactates/sang , Taux de clairance métabolique , Nerfs périphériques , Veine porteRÉSUMÉ
The effects of subcutaneous and intraperitoneal insulin delivery by a closed-loop insulin infusion device on post-prandial hyperglycaemia and rates of glucose appearance and disappearance were compared in alloxan diabetic dogs. No differences in basal or post-prandial values or patterns of response were observed between the two routes of insulin delivery. In addition, the amounts of insulin infused and the plasma insulin concentrations achieved were not different for the two routes of insulin administration. These studies demonstrate that in the dog there appears to be no difference in the pattern of disposal of glucose from a mixed meal when insulin was administered intraperitoneally or subcutaneously at the rates of insulin infusion used in these experiments.
Sujet(s)
Glycémie/analyse , Diabète expérimental/métabolisme , Insuline/administration et posologie , Alloxane , Animaux , Chiens , Aliments , Injections péritoneales , Injections sous-cutanéesRÉSUMÉ
The effects of peripheral venous and portal venous delivery of insulin by a closed-loop insulin infusion device (Biostator GCIIS) on postprandial hyperglycemia and rates of glucose appearance, disappearance, and clearance were compared in alloxan-diabetic dogs. The amounts of insulin required and the peripheral venous plasma insulin concentrations achieved were not different for the two routes of insulin administration. No statistically significant differences in postprandial hyperglycemia or patterns of glucose disposal were observed between the two routes of insulin delivery. These studies indicate that in terms of hepatic versus extrahepatic disposal of glucose, there appears to be no practical advantage of portal venous over peripheral venous administration of insulin when a closed-loop insulin infusion device is used.
Sujet(s)
Glycémie/métabolisme , Diabète expérimental/complications , Hyperglycémie/traitement médicamenteux , Insuline/administration et posologie , Alloxane , Animaux , Diabète expérimental/métabolisme , Chiens , Consommation alimentaire , Hyperglycémie/étiologie , Injections veineuses , Veine porteRÉSUMÉ
We compared the ability of closed-loop intravenous insulin infusion (i.e., an artificial "pancreas"), open-loop continuous subcutaneous insulin infusion, and intensified conventional insulin therapy (preprandial injections of regular insulin, with injection of long-acting zinc-suspension insulin before breakfast) to bring the hyperglycemia of insulin-dependent diabetic subjects to a level comparable to that of normal, nondiabetic subjects. The mean circadian levels of plasma glucose, mean amplitude of glycemic excursions, and M values (defined in Methods) did not significantly differ among the three regimens. Although these levels in the diabetic subjects approximated those in the normal subjects, the levels of plasma insulin, mean amplitude of glycemic excursions, and M values were significantly higher than those in normal subjects (P < 0.01). Therefore, at least on a short-term basis, all three regimens can produce comparable, nearly normal levels of blood sugar in such patients; moreover, closed-loop devices can be used to determine insulin requirements for conventional therapy.
Sujet(s)
Glycémie/métabolisme , Diabète/traitement médicamenteux , Insuline/administration et posologie , Adulte , Diabète/sang , Femelle , Humains , Injections veineuses/instrumentation , Injections sous-cutanées , Insuline/usage thérapeutique , Insuline à longue durée d'action/administration et posologie , Mâle , Adulte d'âge moyenRÉSUMÉ
The Biostator GCIIS was used to clamp circulating glucose at hypoglycemic (42 +/- 1 mg/dl), euglycemic (86 +/- 2 mg/dl), and hyperglycemic (142 +/- 1 mg/dl) levels in normal subjects during a concomitant infusion of insulin (0.1 U/kg/h). Because of limitations in maximal glucose infusion (1 g/min) from the Biostator, a supplementary infusion of glucose was required to accomplish euglycemic and hyperglycemic clamps. The coefficients of variation of blood glucose were 7.06 +/- 1.3%, 5.9 +/- 0.5%, and 6.1 +/- 0.9 for 120 minutes of hypoglycemic, euglycemic, and hyperglycemic clamps, respectively. Despite the occasional interruption of blood flow in the double-lumen catheter and the occasional poor correlation between Biostator and reference glucose method, satisfactory glucose clamps could be maintained for 2 hours.
Sujet(s)
Organes artificiels , Glycémie/métabolisme , Glucose/administration et posologie , Ilots pancréatiques/physiologie , Adulte , Femelle , Humains , Insuline , Mâle , Adulte d'âge moyenRÉSUMÉ
To assess the feasibility of preprogramming an open-loop device with insulin flow rates generated by the Biostator Glucose Controller, comparisons were made in 10 juvenile-onset diabetic patients between meals of equal size and composition taken in the morning, at noon, and in the evening and a bedtime snack during a 24-h period of Biostator glucose control. Four additional diabetic patients had Biostator glucose control for 72 h. Similar amounts of insulin were infused for the meals taken at differing times of the day and, except for the morning meal, for the same meal on two successive days. The meal-related glycemic patterns expressed as mean indices of meal excursions (MIME) were similar for meals of identical size and composition during a single day and for the same meal taken on two consecutive days. Preliminary results using an open-loop device preprogrammed by the Biostator system, although encouraging, underscore the deficiency of the subcutaneous route viz. the delayed entry of insulin into the circulation in achieving normal glucose levels and patterns.